(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Dr. Vinay Prasad's memo raises concerns about COVID-19 vaccines and pediatric mortality - 2Artemis II astronauts channel Apollo 8 with a striking Earthset photo
- 34 Dazzling And Well known Island Objections In US
- 4Incredible Travel Objections for Craftsmanship Darlings to Visit
- 5Magnetic fossils may reveal ancient creature's internal 'GPS system'
- Find the Interesting Universe of Computerized reasoning: the Capability of man-made intelligence
- Dancing through the crackdown: The satirical song soundtracking post-Khamenei Iran
- Struggling to keep your New Year's resolutions? Here's how to keep yourself on track
- The most effective method to Stay away from Normal Traps While Recruiting a Material Organization
- Historical mysteries solved by science in 2025
- Jason Kelce opens about wife Kylie Kelce's past pregnancy loss
- Figure out how to Put resources into Lab Precious stones: A Novice's Aide
- Top Smoothie Flavor: What's Your Mix?
- Oldest evidence of human fire-making discovered at site in England
